RetinaCME
CME

Evolving Protocols in the Treatment of Age-Related Macular Degeneration

Author(s)/Faculty: Rishi P. Singh, MD; Katherine E. Talcott, MD
Release Date: 11/14/2019Expiration Date: 11/13/2020
Credit Type: CMENumber of Credits: 0.75
Content Type: VideoProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, and offers many patients delayed or arrested disease progression as well as the possibility of regaining lost vision. Notable amongst the diseases that have been found to respond well to intravitreal therapy are age-related macular degeneration (AMD), retinal vein occlusion, diabetic macular edema, and, more recently, diabetic retinopathy. The treatment of neovascular AMD has been revolutionized by intravitreal anti–vascular endothelial growth factor (VEGF) therapy. However, long-term extensions of major clinical trials have not demonstrated great success in maintaining the dramatic vision gains obtained initially, particularly when as needed dosing was used. In this rapid response activity, expert faculty will assess new findings pertaining to the optimization of treatment dosing and management of patients with AMD as well as compare injection protocols for their ability to enhance the long-term benefits of anti-VEGF therapy in these patients.